Clinical Trial Update: Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

View source ↗

Summary

A screening study sponsored by Blueprint Medicines is evaluating KIT D816V-mutated clonal mast cell disease in select populations. The study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• AYVAKIT (avapritinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Clonal Mast Cell Disease, KIT D816V Mutation | Status: RECRUITING